Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
58.203,52
-0,06%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Enveric Biosciences Inc (ENVB) Enveric Biosciences Inc (ENVB) Notizie

Enveric Biosciences Inc

ENVB
0,9209
-0,0191 (-2,03%)
02 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/3/202412:00BWEnveric Biosciences Reports Financial Results and Provides..
19/3/202412:00BWEnveric Biosciences Signs Non-Binding Term Sheets to Pursue..
12/3/202412:00BWEnveric Biosciences Announces New Patent Issuances..
11/3/202417:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/3/202413:00EDGAR2Form 8-K - Current report
29/2/202413:00EDGAR2Form 8-K - Current report
29/2/202413:00BWEnveric Biosciences Signs Non-Binding Term Sheets to Pursue..
26/2/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202414:00BWEnveric Biosciences Agrees to Sell Cancer-Targeting..
21/2/202414:05EDGAR2Form 8-K - Current report
21/2/202414:00BWEnveric Biosciences Unveils Library of Preclinical Compounds..
14/2/202421:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202414:05EDGAR2Form 8-K - Current report
06/2/202416:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202423:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202414:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
23/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
11/1/202422:43EDGAR2Form S-3 - Registration statement under Securities Act of..
08/1/202422:42EDGAR2Form 8-K - Current report
03/1/202414:05EDGAR2Form 8-K - Current report
29/12/202322:43EDGAR2Form 8-K - Current report
29/12/202314:52BWEnveric Biosciences Announces Exercise of Warrants and..
28/12/202314:05EDGAR2Form 8-K - Current report
28/12/202314:00BWEnveric Biosciences Selects EB-003 as Lead Drug Candidate..
27/12/202314:05EDGAR2Form 8-K - Current report
27/12/202314:00BWEnveric Biosciences Reports Year End Progress for..
20/12/202314:00BWEnveric Biosciences to Participate in Biotech Showcase 2024..
06/12/202322:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/12/202314:05EDGAR2Form 8-K - Current report
05/12/202314:00BWEnveric Biosciences Selects Development Candidates from..
01/12/202322:31EDGAR2Form S-1/A - General form for registration of securities..
29/11/202314:18EDGAR2Form 8-K - Current report
29/11/202314:00BWEnveric Biosciences Receives Notice of Allowance from USPTO..
27/11/202314:00BWEnveric Biosciences Announces Manuscript Describing the..
24/11/202314:00BWEnveric Biosciences Announces Presentation of Two Posters at..
22/11/202322:30EDGAR2Form 8-K - Current report
13/11/202322:10EDGAR2Form 8-K - Current report
13/11/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:01BWEnveric Biosciences Reports Third Quarter 2023 Corporate and..
06/11/202314:05EDGAR2Form 8-K - Current report
02/11/202322:29EDGAR2Form 8-K - Current report
31/10/202313:05EDGAR2Form 8-K - Current report
31/10/202313:00BWEnveric Biosciences Receives Notice of Allowance from USPTO..
20/10/202314:05EDGAR2Form 8-K - Current report
20/10/202314:00BWEnveric Biosciences to Present at the Centurion One 5th..
18/10/202314:05EDGAR2Form 8-K - Current report
18/10/202314:00BWEnveric Biosciences Initiates GLP Toxicology & Safety..
11/10/202314:05EDGAR2Form 8-K - Current report
Apertura: 0,955 Min: 0,901 Max: 0,955
Chiusura: 0,94

La tua Cronologia

NASDAQ
ENVB
Enveric Biosciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network